Literature DB >> 3057557

Pharmacokinetics of antiepileptic drugs during pregnancy.

I E Leppik1, C A Rask.   

Abstract

During pregnancy, a number of physiologic changes occur that can affect the pharmacokinetics of antiepileptic drugs. Because of its nonlinear kinetics, phenytoin is most affected, with concentrations decreasing to half of prepregnancy values. Carbamazepine and valproate levels also decrease but to a lesser degree. Phenobarbital and primidone levels decrease as well. Some of the changes may be more apparent than real, however, because of changes in antiepileptic drug binding to plasma proteins. It is recommended that concentrations be measured frequently during pregnancy and dose adjustments made as needed. Unbound (free) levels should be measured when drugs known to alter binding are also being taken.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3057557     DOI: 10.1055/s-2008-1041385

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  6 in total

1.  Carbamazepine clearance and seizure stability during pregnancy.

Authors:  Emily L Johnson; Zachary N Stowe; James C Ritchie; D Jeffrey Newport; Melanee L Newman; Bettina Knight; Page B Pennell
Journal:  Epilepsy Behav       Date:  2014-03-13       Impact factor: 2.937

Review 2.  Management of epilepsy during pregnancy: an update.

Authors:  Sima I Patel; Page B Pennell
Journal:  Ther Adv Neurol Disord       Date:  2015-12-27       Impact factor: 6.570

Review 3.  A guide to the safety of CNS-active agents during breastfeeding.

Authors:  C A Chisholm; J A Kuller
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

Review 4.  Pharmacokinetics of valproate in pregnancy: mother-foetus-newborn.

Authors:  S I Johannessen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 5.  Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review.

Authors:  Gali Pariente; Tom Leibson; Alexandra Carls; Thomasin Adams-Webber; Shinya Ito; Gideon Koren
Journal:  PLoS Med       Date:  2016-11-01       Impact factor: 11.069

6.  Magnesium valproate adjuvant therapy on patients with dementia: A protocol for systematic review and meta-analysis.

Authors:  Chen Qi Zhang; Ke Xin Zheng; Ling Qi Sun; Hongbin Sun
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.